Kampanjeplan Nkarta, Inc.
Avansert tidsplan
Enkel graf
Om selskapet
Nkarta, Inc., биофармацевтическая компания, разрабатывает и коммерциализирует клеточную терапию для лечения рака. Подход компании к клеточной иммунотерапии включает химерные антигенные рецепторы на поверхности естественных киллеров (NK), которые позволяют клетке распознавать специфические белки или антигены, присутствующие на поверхности опухолевых клеток. flere detaljer| EBITDA | -0.0203 |
|---|---|
| EV/EBITDA | 0.6554 |
| IPO date | 2020-07-10 |
| ISIN | US65487U1088 |
| Industry | Biotechnology |
| P/BV | 3.36 |
| P/S | 2803808.33 |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Выручка | 0.000115 |
| Див.доход ао | 0 |
| Сайт | http://www.nkartatx.com |
| Цена ао | 3.38 |
| Число акций ао | 0.04901 млрд |
| Prisendring per dag: | 0% (2.35) |
|---|---|
| Prisendring per uke: | +6.82% (2.2) |
| Prisendring per måned: | -9.96% (2.61) |
| Prisendring over 3 måneder: | -48.69% (4.58) |
| Prisendring over seks måneder: | -59.83% (5.85) |
| Prisendring per år: | -62.22% (6.22) |
| Prisendring over 3 år: | -77.12% (10.27) |
| Prisendring over 5 år: | 0% (2.35) |
| Prisendring over 10 år: | 0% (2.35) |
| Prisendring siden begynnelsen av året: | +8.29% (2.17) |
|
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institusjoner | Volum | Dele, % |
|---|---|---|
| RA Capital Management, L.P. | 7805129 | 15.79 |
| NEA Management Company, LLC | 3568781 | 7.22 |
| Adage Capital Partners GP L.L.C. | 3450000 | 6.98 |
| Deerfield Management Company, L.P. (Series C) | 3400000 | 6.88 |
| Samsara BioCapital, LLC | 2868035 | 5.8 |
| COMMODORE CAPITAL LP | 2730000 | 5.52 |
| Blackrock Inc. | 2599201 | 5.26 |
| Wasatch Advisors LP | 2099699 | 4.25 |
| Vanguard Group Inc | 1560518 | 3.16 |
| Boxer Capital, LLC | 1440000 | 2.91 |
| ETF | Dele, % | Lønnsomhet for året, % | Utbytte, % |
|---|---|---|---|
| Vanguard U.S. Momentum Factor ETF | 0.1 | 27.18 | 1.05834 |
| iShares Micro-Cap ETF | 0.07052 | 13.79 | 1.54048 |
| Avantis U.S Small Cap Equity ETF | 0.03005 | 27.77 | 1.68271 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.01681 | 31.36 | 1.41955 |
| Vanguard Russell 2000 ETF | 0.01 | 14.37 | 1.48801 |
ProShares UltraPro Russell2000
|
0.00596 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.0017 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.00031 | 23.61 | 1.43482 |
| Avantis U.S. Equity ETF | 0.00027 | 20.45 | 1.59151 |
| Dimensional US Core Equity Market ETF | 0.00022 | 30.98 | 1.40618 |
| Dimensional U.S. Equity ETF | 0.0002 | 31.53 | 1.3557 |
| Dimensional U.S. Core Equity 2 ETF | 0.0002 | 30.76 | 1.47098 |
| Dimensional U.S. Targeted Value ETF | 0.00017 | 26.01 | 1.93487 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Veileder | Stillingstittel | Betaling | Fødselsår |
|---|---|---|---|
| Mr. Paul J. Hastings | CEO & Director | 938.41k | 1960 (65 år) |
| Dr. Alicia J. Hager | Chief Legal Officer & Corporate Secretary | 590.94k | 1970 (55 år) |
| Dr. Ralph Brandenberger Ph.D. | Chief Technical Officer | N/A | 1969 (56 år) |
| Mr. Greg Mann | Vice President of Public Affairs and Investor Relations | N/A | |
| Dr. David R. Shook M.D. | Chief Medical Officer & Head of Research and Development | N/A | 1978 (47 år) |
| Ms. Alyssa Levin C.A., CPA | Chief Financial & Business Officer and Principal Accounting Officer | N/A | 1985 (40 år) |
| Dr. Nadir Mahmood Ph.D. | President | 1979 (46 år) |
Adresse: United States, South San Francisco, CA , 6000 Shoreline Court - åpne i Google maps, åpne Yandex-kart
Nettsted: http://www.nkartatx.com
Nettsted: http://www.nkartatx.com
